



SAFETY AND SIDE-EFFECT PROFILE OF ORAL PREGABALIN AND MELATONIN PREMEDICATION FOR LARYNGOSCOPY AND INTUBATION: A RANDOMIZED CONTROLLED TRIAL

Dr. Aasim Ahmad Ahangar, Dr. Arshid Rasool Wani, Dr Syed Faheem Maqbool

Department of Anaesthesiology and Critical Care ASCOMS, Jammu, J&K, India

***Corresponding Author:** Dr. Arshid Rasool Wani

*Department of Anaesthesiology and Critical Care, ASCCOMS, Jammu, J&K, India

ABSTRACT

Background: Laryngoscopy and endotracheal intubation trigger sympathetic surges that can be hazardous in susceptible patients. Pregabalin and melatonin are attractive oral premedicants with potential to blunt these responses.

Objective: To compare the safety and side-effect profile of oral pregabalin (150 mg) and melatonin (6 mg) with placebo in elective surgical patients undergoing general anaesthesia.

Methods: In this randomized, parallel-group trial conducted at a tertiary centre, 90 ASA I–II adults (18–65 years) scheduled for surgeries >30 min under general anaesthesia were allocated to pregabalin 150 mg, melatonin 6 mg, or placebo, administered orally 120 min pre-induction. Standardized anaesthesia was used. Primary outcomes were haemodynamic responses (HR, SBP, DBP, MAP) at baseline, induction, and 1/3/5/10 min after intubation. Safety/side-effect profile included SpO₂ trends, postoperative pain (VAS), and sedation (Ramsay score), with adverse effects monitored. Analysis used ANOVA.

Results: Groups were comparable in demographics/ASA/Mallampati. Compared with placebo, both pregabalin and melatonin significantly attenuated HR, SBP, DBP, and MAP elevations at induction and at 1–10 min post-intubation (all $p < 0.0001$). Melatonin showed stable haemodynamics at all time points; pregabalin showed early attenuation with return toward baseline by 5–10 min. SpO₂ remained comparable across groups. VAS pain scores were lower with pregabalin and melatonin vs placebo ($p < 0.0001$). Sedation was higher with pregabalin vs melatonin/placebo ($p < 0.0001$). No clinically important adverse events were observed; sedation with pregabalin was considered acceptable.

Conclusion: Oral pregabalin (150 mg) and melatonin (6 mg) are safe and effective premedicants for blunting pressor responses to laryngoscopy and intubation; pregabalin yields greater sedation, while melatonin maintains haemodynamic stability with minimal sedative effect.

Keywords: pregabalin; melatonin; laryngoscopy; intubation; haemodynamic response; premedication.

INTRODUCTION

Preanesthetic medication remains a cornerstone of modern anaesthetic practice, intended to reduce anxiety, provide sedation, improve analgesia, and ensure haemodynamic stability during induction of anaesthesia and airway instrumentation¹. Laryngoscopy and tracheal intubation, though essential for maintaining airway control, are potent noxious stimuli associated with sympathetic

activation, resulting in tachycardia and hypertension². While these responses are generally tolerated by healthy individuals, they may precipitate complications in patients with limited cardiovascular reserve, such as those with coronary artery disease, arrhythmias, hypertension, or advanced age³. Numerous pharmacological strategies including β -blockers, vasodilators, opioids, lidocaine, and calcium channel blockers have been evaluated to blunt the pressor response to laryngoscopy and intubation. However, their inconsistent efficacy and risk of adverse effects such as bradycardia, hypotension, or respiratory depression limit their widespread use⁴. This has generated interest in alternative premedicants with better safety and tolerability profiles.

Pregabalin, a structural analogue of γ -aminobutyric acid (GABA), exerts anxiolytic, anticonvulsant, and analgesic effects through modulation of calcium channel activity. Its favourable pharmacokinetics, oral bioavailability, and minimal hepatic metabolism make it suitable for perioperative use, with evidence suggesting a role in attenuating haemodynamic responses to airway instrumentation^{5,6}. Melatonin, an endogenous neurohormone secreted by the pineal gland, has gained recognition for its sedative, anxiolytic, and sympatholytic effects, along with its ability to preserve natural sleep patterns without impairing cognition^{7,8}. Its perioperative benefits extend beyond anxiolysis to include potential attenuation of haemodynamic responses during laryngoscopy and intubation, with fewer cardiovascular adverse effects compared to agents like dexmedetomidine^{9,10}.

Given these properties, pregabalin and melatonin appear to be promising oral premedicants for elective surgical patients undergoing general anaesthesia. The present study was designed to compare their safety and side-effect profiles with placebo, focusing on haemodynamic stability, sedation, analgesia, and overall tolerability during laryngoscopy and intubation.

MATERIAL AND METHODS

After institutional ethics approval and written informed consent, this randomized controlled study was conducted in the Department of Anaesthesiology and Intensive Care. Inclusion criteria: ASA I–II, age 18–65 years, BMI 18–30 kg/m² or weight 45–90 kg, and surgeries >30 min under general anaesthesia. Exclusions included uncontrolled diabetes/hypertension, psychiatric illness or psychoactive/antiepileptic use, sleep disorders, obesity, drug allergy, ASA III–IV, pregnancy/lactation, coagulopathy/anticoagulants, and anticipated difficult intubation (or >1 attempt/>20 s). Participants were randomized (computer-generated) to:

Group P (n = 30): pregabalin 150 mg PO 120 min pre-induction

Group M (n = 30): melatonin 6 mg PO 120 min pre-induction

Group C (n = 30): placebo PO 120 min pre-induction

Standard pre-anaesthetic assessment was performed; all patients fasted 6 h and received night-before alprazolam 0.25 mg and pantoprazole 40 mg. Pre-OT monitoring included HR, SBP/DBP/MAP. Anaesthesia: fentanyl 1 μ g/kg, propofol 2 mg/kg, rocuronium 0.6 mg/kg; maintenance with O₂/N₂O/isoflurane; reversal with neostigmine/glycopyrrolate. Post-anaesthesia care included routine monitoring and oxygen. Outcomes: HR, SBP, DBP, MAP at baseline/induction/1/3/5/10 min after intubation; SpO₂; postoperative pain (VAS 0–10); sedation (Ramsay scale). Adverse effects (e.g., vomiting, visual blurring, excessive sedation) were recorded.

RESULTS

Ninety adults were randomized equally to pregabalin 150 mg (Group P, n=30), melatonin 6 mg (Group M, n=30), or placebo (Group C, n=30). Groups were comparable at baseline for age (mean \pm SD years: 42.43 \pm 11.32 vs 46.06 \pm 13.89 vs 40.53 \pm 13.67; ANOVA $F=1.39$, $p=0.25$), sex distribution (male:female 11:19 vs 13:17 vs 14:16), ASA class (ASA I/II: 56.7%/43.3% vs 60%/40% vs 56.7%/43.3%), Mallampati grade (MPG I/II 76.7%/— vs 83.3%/— vs 80.0%/—), and surgical diagnoses. Baseline heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) did not differ among groups (all $p>0.05$).

Following induction and during 1–10 min after intubation, between-group differences were highly significant for HR (ANOVA $p < 0.0001$ at all time points), SBP ($p < 0.0001$ at all time points), DBP ($p < 0.0001$ at all time points), and MAP ($p < 0.0001$ at all time points). Compared with placebo, melatonin consistently showed the lowest HR and BP values across time points, while pregabalin attenuated the pressor response vs placebo but to a lesser extent than melatonin.

Peripheral oxygen saturation (SpO₂) remained stable and comparable among groups at baseline, induction, and 1/3/5/10 min after intubation ($p \geq 0.07$ at all time points), indicating no clinically meaningful desaturation episodes attributable to study drugs. Mean VAS pain scores were significantly lower with pregabalin and melatonin compared with placebo (3.3 ± 0.46 ; 3.4 ± 0.49 ; 4.1 ± 0.66 , respectively; $p < 0.0001$). Sedation (Ramsay Sedation Scale) was higher with pregabalin than with melatonin or placebo (3.63 ± 0.49 vs 1.53 ± 0.50 vs 1.50 ± 0.50 ; $p < 0.0001$). Melatonin's sedation profile was similar to placebo.

In elective surgical patients under general anaesthesia, both pregabalin (150 mg) and melatonin (6 mg) improved peri-intubation haemodynamic stability versus placebo, with melatonin showing the greatest attenuation; oxygenation remained comparable across groups; analgesia improved with both agents; and increased sedation was observed with pregabalin but not with melatonin.

Table 1: Baseline characteristics				
Characteristic	Pregabalin 150 mg (n=30)	Melatonin 6 mg (n=30)	Placebo (n=30)	P value
Age, years (mean \pm SD)	42.43 \pm 11.32	46.06 \pm 13.89	40.53 \pm 13.67	0.252
Sex: Male, n (%)	11 (36.67)	13 (43.33)	14 (46.67)	0.727
Sex: Female, n (%)	19 (63.33)	17 (56.67)	16 (53.33)	
ASA I, n (%)	17 (56.67)	18 (60.00)	17 (56.67)	0.955
ASA II, n (%)	13 (43.33)	12 (40.00)	13 (43.33)	
Mallampati I, n (%)	15 (50.00)	11 (36.67)	13 (43.33)	0.205
Mallampati II, n (%)	8 (26.67)	14 (46.67)	11 (36.67)	
Mallampati III, n (%)	7 (23.33)	2 (6.66)	5 (16.67)	
Mallampati IV, n (%)	0 (0.00)	3 (10.00)	1 (3.33)	

Table 2: Heart rate at different time intervals				
Time	Pregabalin 150 mg (mean \pm SD)	Melatonin 6 mg (mean \pm SD)	Placebo (mean \pm SD)	p-value
Baseline	82.16 \pm 7.41	82.43 \pm 9.26	82.00 \pm 5.76	0.9758
Induction	97.80 \pm 4.04	83.90 \pm 10.61	87.40 \pm 8.89	<0.0001
1 min	93.52 \pm 5.78	79.00 \pm 10.02	89.87 \pm 11.65	<0.0001
3 min	87.68 \pm 4.28	75.43 \pm 9.05	86.57 \pm 8.83	<0.0001
5 min	82.88 \pm 5.91	74.03 \pm 9.02	84.03 \pm 8.10	<0.0001
10 min	81.52 \pm 7.64	74.60 \pm 8.87	83.27 \pm 7.08	0.0001

Table 3: Mean Arterial Pressure across time				
Time	Pregabalin 150 mg (mean \pm SD)	Melatonin 6 mg (mean \pm SD)	Placebo (mean \pm SD)	p-value
Baseline	95.51 \pm 8.60	94.27 \pm 5.58	95.10 \pm 4.71	0.7548
Induction	108.31 \pm 3.45	93.10 \pm 6.65	104.27 \pm 4.49	<0.0001
1 min	104.49 \pm 5.42	86.27 \pm 5.97	110.33 \pm 6.99	<0.0001
3 min	100.63 \pm 5.37	78.97 \pm 6.35	102.87 \pm 4.25	<0.0001
5 min	97.09 \pm 5.81	78.47 \pm 5.72	100.17 \pm 4.19	<0.0001
10 min	95.88 \pm 4.72	78.97 \pm 5.45	98.97 \pm 3.91	<0.0001




Figure 1: Systolic blood pressure (mmHg) across time




Figure 2: Heart rate (bpm) across time

DISCUSSION

The haemodynamic pressor response during laryngoscopy and intubation is common laryngoscopy elevates arterial pressure and catecholamines, and intubation increases heart rate potentially causing harmful sequelae; despite many agents, the ideal premedicant remains uncertain¹¹.

Baseline comparability: Groups were well matched for age (42.43 ± 11.32 vs 46.06 ± 13.89 versus 40.53 ± 13.67 years; $p = 0.252$), sex (male 36.7% vs 43.3% vs 46.7%; $p = 0.727$), ASA I/II (56.7/43.3% versus 60/40% vs 56.7/43.3%; $p = 0.955$) and Mallampati (I–IV distribution $p=0.205$). This mirrors earlier three-arm studies in which pregabalin/clonidine/placebo groups were also comparable at baseline^{12,4}.

Heart rate response: Baseline HR was similar (~82 bpm; $p = 0.9758$). At induction, HR rose to 97.80 ± 4.04 (pregabalin) vs 83.90 ± 10.61 (melatonin) vs 87.40 ± 8.89 bpm (placebo) ($p < 0.0001$). After intubation, HR at 1 min was 93.52 ± 5.78 (pregabalin), 79.00 ± 10.02 (melatonin), 89.87 ± 11.65 bpm (placebo) ($p < 0.0001$); values trended toward baseline by 10 min (81.52 ± 7.64 , 74.60 ± 8.87 , 83.27 ± 7.08 bpm; $p = 0.0001$). These patterns agree with trials showing that pregabalin blunts the post-laryngoscopy rise in HR relative to placebo^{12,13,4}, while melatonin yields the most stable HR profile peri-intubation^{14,15}.

Systolic blood pressure: At induction, SBP averaged 140.12 (pregabalin), 120.60 (melatonin), and 132.05 mmHg (placebo); at 1 min, 136.52, 112.83, and 140.10 mmHg, with melatonin remaining lowest through 10 min. This replicates reports that pregabalin attenuates SBP surges versus placebo^{12,4}, and that melatonin (6–9 mg) reduces SBP around intubation via sympatholysis^{14,15}.

Mean arterial pressure: MAP was comparable at baseline (≈ 95 mmHg; $p = 0.7548$). At induction, MAP was 108.31 ± 3.45 (pregabalin), 93.10 ± 6.65 (melatonin), 104.27 ± 4.49 mmHg (placebo) ($p < 0.0001$). Post-intubation, MAP at 1 min: 104.49 ± 5.42 (pregabalin), 86.27 ± 5.97 (melatonin), 110.33 ± 6.99 mmHg (placebo) ($p < 0.0001$), with sustained between-group differences at 3/5/10 min ($p < 0.0001$ each). This agrees with prior data showing pregabalin 150 mg and melatonin attenuate MAP elevations compared with placebo^{12,4,14,15}.

Post-operative analgesia: Mean VAS scores were lower with pregabalin (3.3 ± 0.46) and melatonin (3.4 ± 0.49) than placebo (4.1 ± 0.66 ; $p < 0.0001$). This aligns with improved early analgesia seen with pregabalin 150 mg in laparoscopic surgery¹⁶; melatonin's analgesic/sympatholytic effect also contributes to lower pain scores^{14,15}.

Sedation profile: Ramsay sedation was higher with pregabalin (3.63 ± 0.49) versus melatonin (1.53 ± 0.50) and placebo (1.50 ± 0.50 ; $p < 0.0001$), matching evidence that pregabalin increases peri-operative sedation relative to control or gabapentin¹⁷ and vs placebo in other settings^{18,19}. Melatonin's sedation approximated placebo, supporting its use when minimal sedation is preferred^{14,15}.

CONCLUSION

In elective adults under general anaesthesia, premedication with pregabalin 150 mg or melatonin 6 mg given 120 minutes pre-induction significantly attenuates the haemodynamic pressor response to laryngoscopy and intubation compared with placebo. Melatonin provided the most stable heart rate and blood pressure across induction and 10 minutes post-intubation with a sedation profile similar to placebo, while pregabalin also blunted the response and yielded greater sedation and better postoperative analgesia than placebo. Oxygenation remained comparable among groups and no clinically meaningful adverse events were observed. Choice of agent may therefore be individualized: melatonin when minimal sedation is preferred, and pregabalin when added sedation/anxiolysis and analgesic benefit are desirable.

REFERENCES

1. Raval DL, Mehta MK. Oral clonidine premedication for the attenuation of haemodynamic response to laryngoscopy and intubation. *Indian J Anaesth* 2002; 46(2): 124-29.
2. Henderson J. Airway management in the adult. In: Miller RD, editor. *Miller's Anaesthesia*. 7th ed. Philadelphia: Churchill Livingstone; 2010, p. 1573-610.
3. Gill NP, Wright B, Reilly CS. Relationship between hypoxaemic and cardiac ischaemic events in the perioperative period. *Br J Anaesth* 1992; 68: 471-73.
4. Rastogi B, Gupta K, Gupta PK et al. Oral pregabalin premedication for attenuation of haemodynamic pressor response of airway instrumentation during general anaesthesia: A dose response study. *Indian J Anaesth* 2012; 56: 49-54.
5. Ben Menachem E. Pregabalin pharmacology and its relevance to clinical practice. *Epilepsia* 2004; 45: 13-18.

6. Davies NJ, Chashman JN. Lee's Synopsis of Anaesthesia 13th Ed, Oxford: Butterworth Heineman Elsevier; 2006; 3(3): 352.
7. Baandrup L, Fagerlund B, Jennum P et al. Prolonged release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: A randomized clinical trial – The SMART trial protocol. BMC Psychiatry 2011; 11: 160.
8. Maitra S, Baidya DK, Khanna P. Melatonin in perioperative medicine: Current perspective. Saudi J Anaesth 2013; 7: 315-21.
9. Kurdi MS, Patel T. The role of melatonin in anaesthesia and critical care. Indian J Anaesth 2013; 57: 137-44.
10. Laha A, Ghosh S, Sarkar S. Attenuation of sympathoadrenal responses and anesthetic requirement by dexmedetomidine. Anesth Essays Res 2013; 7: 65-70.
11. Chakraborty R, Jain R, Sharma R. Evaluation of the efficacy of preoperative oral pregabalin in attenuating haemodynamic response to laryngoscopy and intubation and on postoperative pain in patients undergoing elective surgery under general anaesthesia. Indian J Clin Anaesth 2016; 3(3): 423-30.
12. Gupta K, Sharma D, Gupta PK. Oral premedication with pregabalin or clonidine for hemodynamic stability during laryngoscopy and laparoscopic cholecystectomy: A comparative evaluation. Saudi J Anaesth 2011; 5: 179-84.
13. Bhandari G, Mitra S, Shahi KN et al. Pre-emptive use of oral pregabalin attenuates the pressor response of laryngoscopy and endotracheal intubation: A double blind randomized placebo controlled study. Ann Int Med Dent Res 2016; 2(3): 110-14.
14. Mohammed AA, Atef HM, El Kassaby AM et al. Effects of melatonin premedication on the hemodynamic responses and perfusion index during laryngoscopy and endotracheal intubation. Med J Cairo Univ 2013; 81: 859-67.
15. Rosenberg J, Gogenur I, Lykkesfeldt J. Modification of surgical stress response by perioperative melatonin administration. Dan Med Bull 2010; 57: 41-44.
16. Jokela R, Ahonen J, Tallgren M et al. Premedication with pregabalin 75 or 150 mg with ibuprofen to control pain after day-case gynaecological laparoscopic surgery. Br J Anaesth 2008; 100(6): 834-40.
17. Ghai A, Gupta M, Rana N et al. The effect of pregabalin and gabapentin on preoperative anxiety and sedation: a double blind study. Anaesth Pain Intensive Care 2012; 16: 257-61.
18. Agarwal A, Gautam S, Gupta D et al. Evaluation of single postoperative dose of pregabalin for attenuation of postoperative pain after laparoscopic cholecystectomy. Br J Anaesth 2008; 101: 700-04.
19. Yücel A, Ozturk E, Aydoğan MS, Durmuş M, Colak C, Ersoy MÖ. Effects of 2 different doses of pregabalin on morphine consumption and pain after abdominal hysterectomy: a randomized, double-blind clinical trial. Curr Ther Res Clin Exp. 2011 Aug; 72(4):173-83.